• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Capecitabine + oxaliplatin chemoradiotherapy does not increase survival, but increases toxicity, compared to capecitabine alone in the postoperative treatment of rectal cancer

byGursharan SohiandMichael Pratte
December 3, 2021
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A randomized controlled trial of patients with stage II and III rectal cancer found that adding oxaliplatin to the standard postoperative chemoradiation treatment of capecitabine did not improve survival compared to control patients.

2. Patients who were treated with both oxaliplatin and capecitabine had a higher risk of experiencing toxic side effects.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Colorectal cancer (CRC) is one of the most common malignancies worldwide, with rectal cancer comprising approximately 1/3 of new CRC diagnoses. Postoperative chemoradiotherapy has been shown to reduce recurrence risk and improve survival, although the optimal systemic therapy agents & treatment schedule are not known. This is particularly true in recent years with the introduction of several novel agents which have shown success in preclinical studies, or in treating other forms of cancer. This study is the first randomized trial to assess the efficacy of adding oxaliplatin to routine capecitabine therapy after surgery for resectable rectal cancer. Li et al performed a multicentre, randomized controlled trial beginning in 2008; 589 patients with stage II or III rectal cancer who had undergone surgical excision with negative margins were included. 294 patients were in the control group and 295 were in the intervention group; most patients enrolled had stage III disease. The rate of treatment completion without dose reduction was higher in the control group (74.1%) compared to the oxaliplatin group (66.1%). There was no significant difference in disease-free survival (DFS) between groups; DFS was 76.3% at 3 years and 74.1% at 5 years in the capecitabine group, and was 72.0% at 3 years and 71.1% at 5 years in the oxaliplatin + capecitabine group. Patients in the intervention group were more likely to experience toxic side effects from chemoradiotherapy, and also experienced more high-grade adverse effects compared to the capecitabine-only group. The present trial by Li et al demonstrates that there is likely no role for oxaliplatin in addition to standard capecitabine chemoradiotherapy after operative treatment of rectal cancer.  Oxaliplatin treatment increased the risk of experiencing adverse events without increasing survival. A major strength of this trial was its randomized design, which enables control of confounders, as well as the substantial sample size. A limitation of these findings includes the relatively short follow up of 5 years; the conclusions described here could be strengthened with more data accumulated over time. Additionally, treatment algorithms may vary regionally (i.e., differences in Western countries where rectal cancer is quite prevalent), so the external validity of this trial should be considered when applying findings to clinical practice.

Click to read this study in JAMA Network Open

Relevant Reading: Association between adjuvant chemotherapy and overall survival in patients with rectal cancer and pathological complete response after neoadjuvant chemotherapy and resection

RELATED REPORTS

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer

Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer

#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality

In Depth [randomized controlled trial]: Patient enrollment took place between 2008 and 2015, with trial follow up ending in 2019. Participants were randomized in a 1:1 fashion; blinding was not considered feasible to perform due to the nature of the interventions. The patients in the control group received radiotherapy with concurrent capecitabine (1600mg/m2) in two rounds postoperatively. Those in the intervention group also underwent oxaliplatin infusion on weeks 1, 2, 4 and 5 postoperatively. Both groups also received adjuvant chemotherapy consisting of either capecitabine/oxaliplatin or fluorouracil/leucovorin/oxaliplatin. Patients were followed for a median of 68 months (interquartile range [IQR] 45-96). There were no statistically significant differences in baseline characteristics between the two groups. The primary outcome of disease-free survival was not significantly different between groups. Deaths occurred in 27.9% of the control patients and 29.1% of the oxaliplatin patients over the follow-up period. The hazard ratio (HR) for DFS between the control versus intervention group was 1.07, with a 95% confidence interval (95CI) of 0.79-1.44). There was no significant difference in overall survival between the two groups either, with an HR of 0.93, 95CI 0.64-1.34. The rate of Grade III and IV adverse events in the capecitabine group was 38.6%, compared to 28.6% in the capecitabine-only group; this difference was statistically significant (p=0.01). The capecitabine-only group had lower rates of the following adverse effects in the 6-weeks following treatment completion compared to the intervention group: anorexia, nausea, vomiting, thrombocytopenia, fatigue, neuropathy and ALT:bili ratio increase.

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: carboplatincolorectal canceroxaliplatinrectal cancer
Previous Post

Smartphone-based intervention reduced body mass index and obesity in school children

Next Post

#VisualAbstract Patient-led surveillance after treatment of localized melanoma is safe, feasible, and acceptable compared to clinician-led surveillance

RelatedReports

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
StudyGraphics

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer

June 13, 2025
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Gastroenterology

Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer

April 16, 2025
#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality
StudyGraphics

#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality

April 7, 2025
Development of a risk index for colorectal cancer screening
Chronic Disease

Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer

April 3, 2025
Next Post
#VisualAbstract Patient-led surveillance after treatment of localized melanoma is safe, feasible, and acceptable compared to clinician-led surveillance

#VisualAbstract Patient-led surveillance after treatment of localized melanoma is safe, feasible, and acceptable compared to clinician-led surveillance

Calcium does not significantly improve return of spontaneous circulation in adults with out-of-hospital cardiac arrest

Compliance-linked incentives increase infant immunizations rates in rural India

2 Minute Medicine Rewind December 6, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.